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Background: Paraoxonase 1 (PON1) is an enzyme that possesses anti-atherogenic and anti-inflammatory properties
with serum levels determined by genetic and exogenous factors. Lower serum PON1 arylesterase activity is
associated to metabolic alterations related to childhood overweight and onset and/or development of diabetes
and CVD later in life. However, data on the relationship between genetic PON1 polymorphisms and nutritional
status as well as lipid profile in children are limited.
To investigate the distribution of the C(−107)T PON1 gene polymorphism and its relation with serum PON1 enzyme
activity, nutritional status and lipid profile in children.
Methods: A cross-sectional study was performed including 73 children aged 5 to 7 years who attended public pediatric
clinics. PON1 C(−107)T, arylesterase activity, body mass index for the age, and serum lipid profile were evaluated.
Results: PON1 activity was higher in overweight children compared to the normal weight ones (p= 0.02). The genotypic
frequency did not differ between the two groups (p> 0.05). Carriers of CC genotype had higher enzyme activity than T
allele carriers, and this difference was greater among normal weight children. HDL levels were higher among normal
weight children carrying CC genotype, compared to those carrying the T allele (p< 0.01).
Conclusion: The PON1 C(−107)T polymorphism is associated with higher serum enzyme activity in children, as observed
previously in adults. In addition, this polymorphism also shows association to higher high density lipoprotein (HDL) levels
and serum PON1 arylesterase activity in the normal weight children studied.
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Human paraoxonase-1 (PON1) is a calcium-dependent
esterase, synthesized primarily in the liver, which
circulates in the bloodstream associated to high-density
lipoprotein (HDL) [1]. Originally, the PON1 was identi-
fied for hydrolyzing organophosphates, and its name
refers to the enzyme’s ability to degrade paraoxon
(paraoxonase activity) [1]. In addition, the enzyme
degrades lipophilic lactones (lactonase activity),* Correspondence: sandra.valle@ufpel.edu.br
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[1]. Studies reported that PON1 plays a significant anti-
oxidant activity of HDL by protecting low-density lipo-
proteins (LDL) to lipid peroxidation and, thereby,
attenuates the development of atherosclerosis [1–3].
Moreover, PON1 modulates the anti-inflammatory role
of HDL and exerts a defensive effect against atherogenic
changes, like homocysteinylation of HDL and LDL [1].
Finally, increased serum PON1 activities are associated
to the reduction of endothelial damage and cardiovascu-
lar disease (CVD) risk [2, 3].
Several polymorphisms in the coding and promoter
regions of the PON1 gene (including PON1192,
PON155, PON1−162, PON1−832, PON1−909, PON1−1076,le is distributed under the terms of the Creative Commons Attribution 4.0
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the enzyme’s activity and/or concentration [1, 4, 5].
Among the genetic changes, the single nucleotide poly-
morphism (SNP) identified in the position −107 in pro-
moter region of the PON1 gene exerts significant
effects on serum activity [6, 7]. It contributes with up
to 25% of the variations in the PON1 expression in
Caucasian adults, and the presence of the C allele re-
sults in PON1 levels up to twice higher than for car-
riers of the T allele [6, 8, 9]. The PON1 T(−107)C SNP
accounts for approximately 12% of the serum activity
variability between individuals, contributing more than
other SNP, even in combination with exogenous factors
[10]. For that reason, we choose this SNP for the current
study. A number of SNP affect the enzyme catalytic effi-
ciency for some substrates such as paraoxon [10]. There-
fore, the use of phenyl acetate provides a better indication
of the enzyme activity in the serum [10].
A two- or threefold rise in childhood overweight has been
identified in recent years in developed and in developing
countries [11]. The childhood overweight and overweight-
related issues, such as obesity, dyslipidemia, glucose intoler-
ance, and hypertension, are important subjects of debate in
children’s health at this moment [5, 11]. These conditions
have been considered as risk factors leading to CVD un-
timely [5]. However, few studies have analyzed the activity of
PON1 in children and its association with weight and risk
factors for CVD. In particular, one study performed aimed
to genotype and identify the frequency of PON1 C(−107)T
in a children population and observed that the frequency of
both alleles was very similar [9]. Moreover, it has verified
that the PON1 arylesterase activity was significantly higher
in children homozygous for the C allele [9].
The serum PON1 activity also is affected by a number
of exogenous factors such as nutritional and health sta-
tus [7, 10]. In a recent study, children, 12 year-olds, with
body mass index (BMI) > 95th percentile had signifi-
cantly lower PON1 levels in comparison to normal
weight [12]. In addition, lower serum PON1 lactonase
and arylesterase activities are associated to metabolic al-
terations related to childhood overweight and onset and/
or development of diabetes and CVD later in life [1, 5].
Nevertheless, data on the relationship between PON1
and nutritional status as well as lipid profile in childhood
are limited and sometimes controversial, mainly due to
differences in measurement techniques and data analysis
[13, 14]. Such situation is expected to be clarified by the
analysis of the interaction between gene, PON1 aryles-
terase activity, and nutritional status. The present study
aims to investigate the distribution of the C(−107)T
PON1 gene polymorphism and its relation with serum
PON1 enzyme activity, nutritional status and lipid pro-
file in a population of children assisted by pediatric
clinics of two cities in southern Brazil.Methods
Study population
The sample of this study is part of a cross-sectional
study on the activity of PON1 and its associated factors
in children aged 5–7 years old, from Rio Grande do Sul
(RS), Brazil. The study was conducted from January to
October 2014 with children attending the pediatric clinic
of the College of Medicine/Universidade Federal de Pe-
lotas (UFPEL) in Pelotas–RS, Brazil and the pediatric
clinic of Pinheiro Machado–RS, Brazil. Children
diagnosed with liver diseases, cerebral palsy, bone
dysplasia or neoplasia, and those with special needs
(physical or motor) and with genetic alterations such as
Down syndrome and thalassemia were excluded.
All children referred to pediatric clinics during data
collection were assessed, being invited to participate in
the study are those who did not have any exclusion cri-
teria. Information on the age and sex of the child were
collected from medical records, anthropometric mea-
surements were performed, and children were referred
for blood collection in a clinical laboratory.
Ethics statement
All procedures followed were in accordance with the
ethical standards, and study protocols were approved by
the Ethics Committee on Human Research of College of
Medicine/Universidade Federal de Pelotas (Report num-
ber: 654.439). Consent was obtained at the time of en-
rollment by the study staff. The parents or guardians of
the children were informed concerning the purpose and
procedures of the study before written consent was ob-
tained. The child’s consent was obtained orally before
the beginning of the evaluations.
Anthropometric measurements
Weight and height data were measured using a digital
platform scale (Welmy®) with 150 kg capacity and 100 g
accuracy, and an attached stadiometer with 200 cm
capacity and 0.5 cm precision. Anthropometric measure-
ments were taken twice by trained interviewers, being
the average of the two measures used in the analysis. To
assess the nutritional status, the body mass index (BMI)
for age in z score was used, as recommended by the
World Health Organization, 2007, through the Anthro-
Plus program [15]. Children with BMI-for-age> + 1SD
were classified as overweight.
Biochemical analyses
After a 12-hour fasting period, 7-ml blood samples were
collected in the clinical laboratory, between 8 a.m. and 10
a.m. The samples were centrifuged, and the serum was
immediately used for verifying serum lipids. Total choles-
terol (TC) (Biosystems, RJ, BR), the cholesterol linked to
high-density lipoproteins (HDL-C) (Biosystems, RJ, BR),
Table 1 General characteristics and biochemical laboratory data
from normal weight and overweight children aged 5–7, Pelotas,






Sex; F:M≠ 20/23 16/14 0.66
Mean (SD) Mean (SD)
Age (years)b 5.9 (0.8) 5.9 (0.8) >0.99
HDL-C (mg/dL)b 52.8 (12.8) 50.0 (15.0) 0.39
LDL-C (mg/dL)b 85.1 (30.3) 93.7 (28.8) 0.22
Median (p25–p75) Median (p25–p75)
TC (mg/dL)a 162.0 (125.0–179.0) 165.0(137.0–187.0) 0.29
TAG (mg/dL)a 60.0(50.0–86.0) 71.5(56.0–84.0) 0.17
PON1 activity (kU/L)a 77.6(64.1–96.1) 97.2(78.7–105.5) 0.02
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
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by the enzymatic colorimetric test, following manufac-
turer’s instructions. The cholesterol linked to low-density
lipoproteins (LDL-C) was calculated by the Friedewald
formula. The reference values considered adequate were
those proposed in I guidelines for atherosclerosis preven-
tion in childhood and adolescence, developed by the
Brazilian Society of Cardiology [16].
Determination of PON1 arylesterase activity levels
To measure the arylesterase activity of PON1, the serum
samples were frozen and kept at −20 °C until further
analysis. The arylesterase activity of PON1 was mea-
sured in duplicate, using phenyl acetate as substrate.
The enzymatic activity was calculated from the rate of
formation of phenol by increasing the absorbance at
270 nm, at 25 °C in a spectrophotometer (FEMTO®).
Samples were diluted 1:3 in buffer 20 mM Tris/HCl (Sigma
Chemical Co., St. Louis, USA), pH 8.0, containing 1 mM of
CaCl2 (Vetec Chemical Co., RJ, Br). The reagent solution
was composed by the buffer, to which it was added 1 mM of
phenyl acetate (Sigma Chemical Co., St. Louis, USA). The
reaction was determined after 20 s of retention, and the
absorbance was measured for 60 s. It was considered one
unit of PON1 arylesterase activity equal to 1 μM phenol/
minute, expressed in kU/L, based on the phenol extinction
coefficient. Blank samples containing deionized water
were used to correct non-enzymatic hydrolysis.
Genotyping
Genomic DNA was extracted from heparinized blood
samples according to standard procedures and quantitated
using a spectrophotometer. The SNP was determined by
polymerase chain reaction (PCR), followed by restriction
enzyme digestion (BsrBI), and agarose gel electrophoresis.
The amplification by PCR of PON1 C(−107)T was
performed using the primers: forward 5′- AGC-TAG-CTG-
CGG-ACC-CGG-CGG-GGA-GGA-G -3′ and reverse
5′- GGC-TGC-AGC-CCT-CAC-CAC-AAC-CC -3′. The
amplification program included an initial denaturation
step at 94 °C for 5 min, followed by 35 cycles of de-
naturation at 94 °C for 45 s, annealing at 67 °C for
45 s, extension at 72 °C for 45 s, and a final exten-
sion at 72 °C for 10 min. The PCR products were
digested at 37 °C for 2 h using BsrBI (New England
Bio Labs, Cambridge, UK). The lower case base in PON1
(−107) upstream primer indicates a mismatch, introducing a
restriction site for BsrBI enzyme, because there is no specific
restriction site cutting the DNA original sequence. After di-
gestion, the C allele was identified by 28 and 212-bp frag-
ments, whereas the T allele resulted in a no-digested 240-bp
fragment. DNA fragments were separated by electrophoresis
on 3% high-resolution agarose gel (Kasvi, Parana, BR),
stained with SYBR Safe (Applied Biosystems).Statistical analysis
Data were double entered in Microsoft Excel 2010 and an-
alyzed in STATA software, version 12.0 (Stata Corp., Col-
lege Station, USA). Initially, the normality of the data was
tested from the Shapiro-Wilk test. The description of the
variables was performed using absolute and relative fre-
quencies for categorical variables. For numeric variables,
mean and standard deviation (SD) and median and inter-
quartile range were used (p25–75) in the case of not ap-
proximately normal variables. PON1 activity, according to
major categorical exposures was assessed by Student’s t
test, Mann–Whitney, or Kruskal–Wallis, depending on
the nature of the variables. Allele frequencies were de-
duced from the genotype distribution. The χ2 test was
used to test the Hardy–Weinberg equilibrium (HWE),
with the observed and expected frequencies obtained. The
distribution of nutritional status among sex or genotypes
was also compared by the χ2 test. P values less than 0.05
were considered to indicate statistical significance.
Results
For the analyses, 73 children were included, composed of
37 males (50.7%). The median PON1 arylesterase activity
was 86.5 (66.6 to 103.6 kU/L) , being similar between boys
(84.8 ± 24.3 kU/L) and girls (90.2 ± 28.9 kU/L) (p = 0.50).
Among all evaluated parameters, differences were ob-
served across sex only for TAG (p = 0.03). Table 1 shows
the main demographic and biochemical characteristics of
the studied population, stratified by nutritional status. Of
all children evaluated, 41.1% (n = 30) were overweight.
Overweight children had higher PON1 activity than that
of the normal weight group (p = 0.02).
The allelic frequency for the PON1 C(−107)T genotype
was 60% for the C allele and 40% for T allele. The
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confirmed (p = 0.38). The genotype frequency and the
enzyme activity are presented in Table 2. The analysis
revealed that the most frequent genotype was the CT
(52.1%). Children with the CC genotype had higher
levels of serum PON1 activity (p < 0.05). The frequency
analysis of genotypes CC, CT, and TT among normal
weight and overweight children was not different.
For comparing enzyme activity and lipid profile be-
tween groups, patients carrying the T allele were
grouped into a single category and compared to those
homozygous for the C allele. Even after the stratification
by nutritional status, serum PON1 activity was higher
among patients with the CC genotype (p < 0.05). HDL-C
serum concentrations were significantly higher in nor-
mal weight children, carrying CC genotype, compared to
carriers of the T allele. The levels of TC, LDL-C, and
TAG were not different between groups, even after
stratified by sex (p > 0.05) (Table 3).
Discussion
The results of the current study indicated that children
with the CC genotype for the PON1 C(−107)T poly-
morphism had higher serum PON1 activity than carriers
of the T allele. In addition, serum concentrations of HDL-
C were higher in normal weight children of the CC geno-
type. The association between the CC genotype and
higher serum PON1 activity and HDL-C concentrations
in normal weight children creates a protective profile
against the development of CVD already in early ages and
supports the idea that a favorable environment and gen-
etic predisposition can play a role in disease development.
PON1 arylesterase activity was, as expected, similar for
both sexes and also similar to the average PON1 activity
for infant populations assessed using phenyl acetate as
substrate [12, 17]. Similar results have been reported by
other studies [18]. Moreover, in the CHAMACOS
Mexican cohort, the authors observed that the average
PON1 activity in children raised from age five to seven
was similar between boys and girls [19].
The genotypic and allelic frequencies of the studied
sample were also similar to those found in Mexican chil-
dren [19], in contrast to observed in Caucasian adultTable 2 Serum PON1 activity and genotype distribution in
children aged 5–7, Pelotas, RS, Brazil, 2015. (n = 73)
PON1
C(−107)T
Genotype PON1 activity (kU/L)*
n Frequency (%) Median p25–75
CC 25 34.2 103.0 83.4–113.9
CT 38 52.1 83.3 66.5–97.2
TT 10 13.7 68.0 63.5–78.7
Total 73 100.0 86.5 66.6–103.6
*Kruskal–Wallis test. p < 0.01populations, where the C and T alleles frequencies were
close to 50% [8, 20].
Children of the CC genotype had the highest serum
PON1 activity. This finding is in agreement with a previ-
ous report in children, when it was found that those
with the CC genotype had higher PON1 activity than
children carrying T allele [9]. In addition, this relation-
ship between the genotype and PON1 activity was
greater in normal weight children [21], which is associ-
ated with the fact that PON1 arylesterase activity is dir-
ectly proportional to the protein concentration [22].
PON1 sequencing and haplotype analyses have shown
that the C(−107)T PON1 promoter polymorphism is the
strongest known predictor of PON1 gene expression and
protein levels [20]. Moreover, there is evidence of a mo-
lecular mechanism involving C(−107)T PON1 and the
binding of the transcription factor Sp1 [6]. This mechan-
ism is consistent with the association between the C al-
lele and higher expression of the PON1 gene, serum
protein concentration and serum activity, indicating that
the transcription factor binds to its site with more affin-
ity in the variant −107C. In contrast, the −107T reduces
the affinity of the Sp1 transcription factor to its binding
site, resulting in lower protein concentrations of PON1
for this allele [6].
The association between excess weight in childhood
and PON1 SNPs is still poorly investigated [23, 24]. In
particular, the association of PON1 C(−107)T and the
nutritional status of children have been not studied yet.
In our study, we verified that the genotypic distribution
was similar between normal weight and overweight
children, suggesting that this SNP did not influence the
nutritional status.
Many authors have found that there is a reduction in
serum PON1 activity in obese children and adolescents
compared to those of normal weight [5, 12, 18, 25, 26].
Our results are consistent with others [27, 28] that
assessed children of a very similar age group, and found
that PON1 activity was higher in obese children than in
those of normal weight. Furthermore, studies in adoles-
cents also found similar results [29]. It is possible that
the complex nature of obesity, which depends on both
genetic and environmental factors, is a confounding fac-
tor, resulting in conflicting results about the relationship
between the SNP and PON1 activity in children. In this
sense, the influence of the gene-environment relation of
PON1 activity requires further investigation.
We verified that normal weight children of the CC
genotype had HDL-C levels higher than those carrying
at least one T allele. These results are in agreement with
a study with elderly Italians [30]. One possible interpret-
ation for this effect refers to an increased concentration
of PON1 bound to HDL apolipoproteins that may play a
role in the metabolism of lipoproteins, improving its
Table 3 Relationship of PON1 C(−107)T with the lipid profile of normal weight and overweight children aged 5–7, Pelotas, RS, Brazil,
2015. (n = 73)
PON1 C(−107)T P value
CC CT+TT
Median (p25–75)
PON1 activity(kU/L)a Normal weight 94.6 (72.3–114.8) 68.5 (63.5–86.7) <0.01
Overweight 103.6 (100.9–113.0) 94.0 (73.0–102.4) 0.04
TC (mg/dl)a Normal weight 162.0 (141.0–188.0) 165.0 (125.0–175.0) 0.38
Overweight 165.5 (154.0–183.0) 167.0 (132.0–187.0) 0.48
TAG (mg/dl)a Normal weight 63.0 (52.0–71.0) 54.0 (48.0–86.0) 0.75
Overweight 78.0 (62.0–85.0) 62.0 (55.0–78.0) 0.40
Mean (SD)
HDL-C (mg/dl)b Normal weight 59.8(11.6) 49.0(12.0) <0.01
Overweight 49.0(16.6) 50.5(14.6) 0.80
LDL-C (mg/dl)b Normal weight 85.7(28.1) 84.7(31.8) 0.92
Overweight 101.0(17.9) 89.8(32.9) 0.32
PON1 paraoxonase1, TC total cholesterol, TAG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
aMann-Whitney test
bStudent’s t test
Uliano et al. Nutrire  (2016) 41:20 Page 5 of 6functionality [30]. It indicates that normal weight chil-
dren of the CC genotype, in addition to increased PON1
activity, also have higher HDL-C levels, suggesting a
profile indicator of increased protection against oxidative
damage, thus preventing the development of early endo-
thelial injuries.
Recent studies have pointed out that vitamins A, E,
and C supplementation have an impact in restoring the
decreased paraoxonase activity following different oxida-
tive stress-causing conditions [31]. Moreover, they have
verified that, despite the differential response of genetic
polymorphisms, some vitamin and antioxidant com-
pounds exert protective action on the PON1 arylesterase
activity [31]. The investigation of this important aspect
was not possible in our study, since only 6 children, in a
total of 73, have used dietary supplements 90 days before
the interview.
Finally, it is important to highlight the limitation of
the present study. In our analysis, the sample size is ap-
propriate for the study of the genotype distribution but
can be considered small for the analyses by subgroup of
weight category, something that may limit the extrapola-
tion of our observations to the general population.
Surely, it would be interesting to perform a study with a
higher sample size, in order to clarify in more detail the
association between the PON1 polymorphism and nutri-
tional status over the enzyme activity.
Conclusion
We conclude that PON1 C(−107)T polymorphism is asso-
ciated with higher serum enzyme activity in children, asobserved previously in adults. In addition, this polymorph-
ism also shows association to higher HDL levels and serum
PON1 arylesterase activity in the normal weight children
studied.
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